Physician profile
James M Koch
NPI 1689649337
$2,685.90
in general payments reported to CMS, 2019-2025
17 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $381 · 2021: $239 · 2022: $183 · 2023: $358 · 2024: $514 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,332.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $854.36 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $367.05 | 2021-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $291.12 | 2021-2025 | Verquvo |
| Esperion Therapeutics, INC. | $248.58 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.43 | 2021-2025 | Jardiance |
| Scpharmaceuticals INC. | $115.20 | 2025 | |
| Medtronic Vascular, INC. | $111.27 | 2019 | |
| Astellas Pharma US INC | $107.39 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $76.97 | 2024 | Farxiga, Wainua |
| Lexicon Pharmaceuticals, INC. | $71.37 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals, LTD. | $67.90 | 2021 | |
| Abiomed | $43.47 | 2024 | Impella |
| Philips North America LLC | $40.63 | 2022-2023 | |
| Abbott Laboratories | $22.41 | 2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $20.21 | 2024 | Xarelto |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $18.82 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.72 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Koch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.